For a long time, Sunshine Biopharma (SBFM) has been attempting to market its several candidates to battle against covid-19. Today it is working to develop PLpro and SBFM-PL4 in collaboration with the University of Georgia, College of Pharmacy. Besides them, Sunshine is aiming to improve Adva-27a, an anticancer medicine. With all of these development programs, SBFM couldn’t climb even more than $5 when most of the popular biotech shares are priced over $10.
Obviously Sunshine is seeking more funds to inject into current covid-19 and anticancer treating programs. Therefore, it is offering 1,882,353 units to raise $8 million to the public. SBFM’s Warrants are coming to a stage of Nasdaq at the price of $0.01. At the time of writing the stock is trading at $2.31.